An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group
- PMID: 24452673
- DOI: 10.1002/cncr.28392
An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group
Abstract
Background: The European Organization for Research and Treatment of Cancer (EORTC) 24954 phase 3 randomized clinical trial compared 2 schemes of combined chemotherapy for patients with resectable cancers of the hypopharynx and larynx: sequential induction chemotherapy and radiotherapy versus alternating chemoradiotherapy. The current study reports detailed effects of both treatment arms on health-related quality of life (HRQOL) and symptoms.
Methods: A total of 450 patients aged 35 years to 76 years (World Health Organization performance status (WHO PS) ≤ 2) with untreated, resectable advanced squamous cell carcinoma of the larynx (tumor classification of T3-T4) or hypopharynx (tumor classification of T2-T3-T4) with regional lymph nodes in the neck classified as N0 to N2 with no metastases were randomized in this prospective phase 3 trial into either the sequential arm (control) or the alternating arm (experimental). QOL assessment was performed at randomization; at baseline; at 42 days; and at 6, 12, 24, 36, and 48 months.
Results: There were no observed differences with regard to the primary endpoint of Fatigue and secondary endpoint of Dyspnea. Significant differences were found in the secondary endpoints of Swallowing and Speech problems at 42 days after randomization in favor of patients in the sequential arm. Explanatory and sensitivity analysis revealed that the primary analysis favored the sequential arm, but the majority of differences in HRQOL did not exist at the end of treatment, and returned to baseline levels.
Conclusions: In the current study, a trend toward worse scores was noted in the patients treated on the alternating chemoradiotherapy arm but very few differences reached the level of statistical significance. The HRQOL scores of the majority of patients returned to baseline after therapy.
Trial registration: ClinicalTrials.gov NCT00002839.
Keywords: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30); alternating chemoradiotherapy; chemotherapy; health-related quality of life; hypopharynx cancer; larynx cancer; radiotherapy.
© 2013 American Cancer Society.
Publication types
MeSH terms
Associated data
Grants and funding
- 2U10 CA11488-25/CA/NCI NIH HHS/United States
- 5U10 CA11488-26/CA/NCI NIH HHS/United States
- 5U10 CA11488-27/CA/NCI NIH HHS/United States
- 5U10 CA11488-28/CA/NCI NIH HHS/United States
- 5U10 CA11488-29/CA/NCI NIH HHS/United States
- 5U10 CA11488-30/CA/NCI NIH HHS/United States
- 5U10 CA11488-31/CA/NCI NIH HHS/United States
- 5U10 CA11488-32/CA/NCI NIH HHS/United States
- 5U10 CA11488-33/CA/NCI NIH HHS/United States
- 5U10 CA11488-34/CA/NCI NIH HHS/United States
- 5U10 CA11488-35/CA/NCI NIH HHS/United States
- 5U10 CA11488-36/CA/NCI NIH HHS/United States
- 5U10 CA11488-37/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
